

55. Bolderson, E., Tomimatsu, N., Richard, D.J., Boucher, D., Kumar, R., Pandita, T.K., Burma, S., and Khanna, K.K. (2010). Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. *Nucleic Acids Res.* 38, 1821–1831. <https://doi.org/10.1093/nar/gkp1164>.
56. Bindra, R.S., Crosby, M.E., and Glazer, P.M. (2007). Regulation of DNA repair in hypoxic cancer cells. *Cancer Metastasis Rev.* 26, 249–260. <https://doi.org/10.1007/s10555-007-9061-3>.
57. Ng, N., Purshouse, K., Foskolou, I.P., Olcina, M.M., and Hammond, E.M. (2018). Challenges to DNA replication in hypoxic conditions. *FEBS Journal* 285, 1563–1571. <https://doi.org/10.1111/febs.14377>.
58. Pires, I.M., Bencokova, Z., Milani, M., Folkes, L.K., Li, J.-L., Stratford, M.R., Harris, A.L., and Hammond, E.M. (2010). Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. *Cancer Res.* 70, 925–935. <https://doi.org/10.1158/0008-5472.CAN-09-2715>.
59. Chan, N., Koritzinsky, M., Zhao, H., Bindra, R., Glazer, P.M., Powell, S., Belmaaza, A., Wouters, B., and Bristow, R.G. (2008). Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. *Cancer Res.* 68, 605–614. <https://doi.org/10.1158/0008-5472.CAN-07-5472>.
60. Kim, I.-K., Stegeman, R.A., Brosey, C.A., and Ellenberger, T. (2015). A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase. *J. Biol. Chem.* 290, 3775–3783. <https://doi.org/10.1074/jbc.M114.624718>.
61. Hegde, M.L., Izumi, T., and Mitra, S. (2012). Oxidized base damage and single-strand break repair in mammalian genomes: role of disordered regions and posttranslational modifications in early enzymes. *Prog. Mol. Biol. Transl. Sci.* 110, 123–153. <https://doi.org/10.1016/B978-0-12-387665-2.00006-7>.
62. Zheng, F., Zhang, Y., Chen, S., Weng, X., Rao, Y., and Fang, H. (2020). Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. *Biomed. Pharmacother.* 123, 109661. <https://doi.org/10.1016/j.biopha.2019.109661>.
63. Rose, M., Burgess, J.T., O'Byrne, K., Richard, D.J., and Bolderson, E. (2020). PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. *Front. Cell Dev. Biol.* 8, 564601. <https://doi.org/10.3389/fcell.2020.564601>.
64. Murata, M.M., Kong, X., Moncada, E., Chen, Y., Imamura, H., Wang, P., Berns, M.W., Yokomori, K., and Digman, M.A. (2019). NAD<sup>+</sup> consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival. *Mol. Biol. Cell* 30, 2584–2597. <https://doi.org/10.1091/mbc.E18-10-0650>.
65. Palermo, V., Rinalducci, S., Sanchez, M., Grillini, F., Sommers, J.A., Brosh, R.M., Jr., Zolla, L., Franchitto, A., and Pichierri, P. (2016). CDK1 phosphorylates WRN at collapsed replication forks. *Nat. Commun.* 7, 12880. <https://doi.org/10.1038/ncomms12880>.
66. Bian, L., Meng, Y., Zhang, M., and Li, D. (2019). MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. *Mol. Cancer* 18, 169. <https://doi.org/10.1186/s12943-019-1100-5>.
67. Ikenoue, T., Togo, G., Nagai, K., Ijichi, H., Kato, J., Yamaji, Y., Okamoto, M., Kato, N., Kawabe, T., Tanaka, A., et al. (2001). Frameshift mutations at mononucleotide repeats in RAD50 recombinational DNA repair gene in colorectal cancers with microsatellite instability. *Jpn. J. Cancer Res.* 92, 587–591. <https://doi.org/10.1111/j.1349-7006.2001.tb01134.x>.
68. Alemayehu, A., and Fridrichova, I. (2007). The MRE11/RAD50/NBS1 complex destabilization in Lynch-syndrome patients. *Eur. J. Hum. Genet.* 15, 922–929. <https://doi.org/10.1038/sj.ejhg.5201858>.
69. Neal, J.A., Dunger, K., Geith, K., and Meek, K. (2020). Deciphering the role of distinct DNA-PK phosphorylations at collapsed replication forks. *DNA Repair* 94, 102925. <https://doi.org/10.1016/j.dnarep.2020.102925>.
70. Zolner, A.E., Abdou, I., Ye, R., Mani, R.S., Fanta, M., Yu, Y., Douglas, P., Tahbaz, N., Fang, S., Dobbs, T., et al. (2011). Phosphorylation of polynucleotide kinase/phosphatase by DNA-dependent protein kinase and Ataxia-telangiectasia mutated regulates its association with sites of DNA damage. *Nucleic Acids Res.* 39, 9224–9237. <https://doi.org/10.1093/nar/gkr647>.
71. Weinfeld, M., Mani, R.S., Abdou, I., Aceytuno, R.D., and Glover, J.N.M. (2011). Tidying up loose ends: the role of polynucleotide kinase/phosphatase in DNA strand break repair. *Trends Biochem. Sci.* 36, 262–271. <https://doi.org/10.1016/j.tibs.2011.01.006>.
72. Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P.W., Levine, D.A., et al. (2013). Inferring tumour purity and stromal and immune cell admixture from expression data. *Nat. Commun.* 4, 2612. <https://doi.org/10.1038/ncomms3612>.
73. Gibbs, D.L. (2020). Robust classification of Immune Subtypes in Cancer. <https://doi.org/10.1101/2020.01.17.910950>.
74. Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., and Alizadeh, A.A. (2015). Robust enumeration of cell subsets from tissue expression profiles. *Nat. Methods* 12, 453–457. <https://doi.org/10.1038/nmeth.3337>.
75. Sevenich, L. (2019). Turning “cold” into “hot” tumors-opportunities and challenges for radio-immunotherapy against primary and metastatic brain cancers. *Front. Oncol.* 9, 163. <https://doi.org/10.3389/fonc.2019.00163>.
76. DeBerardinis, R.J., and Chandel, N.S. (2016). Fundamentals of cancer metabolism. *Sci. Adv.* 2, e1600200. <https://doi.org/10.1126/sciadv.1600200>.
77. Hitosugi, T., and Chen, J. (2014). Post-translational modifications and the Warburg effect. *Oncogene* 33, 4279–4285. <https://doi.org/10.1038/nc.2013.406>.
78. Pégrier, J.-P., Le May, C., and Girard, J. (2004). Control of gene expression by fatty acids. *J. Nutr.* 134, 2444S–2449S. <https://doi.org/10.1093/jn/134.9.2444S>.
79. Nusinow, D.P., Szpyt, J., Ghandi, M., Rose, C.M., McDonald, E.R., 3rd, Kalocsay, M., Jané-Valbuena, J., Gelfand, E., Schweppe, D.K., Jedrychowski, M., et al. (2020). Quantitative proteomics of the cancer cell line encyclopedia. *Cell* 180, 387–402.e16. <https://doi.org/10.1016/j.cell.2019.12.023>.
80. Schönfeld, P., and Reiser, G. (2013). Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain. *J. Cereb. Blood Flow Metab.* 33, 1493–1499. <https://doi.org/10.1038/jcbfm.2013.128>.
81. Gizak, A., Wiśniewski, J., Heron, P., Mamczur, P., Sygusch, J., and Rakus, D. (2019). Targeting a moonlighting function of aldolase induces apoptosis in cancer cells. *Cell Death Dis.* 10, 712. <https://doi.org/10.1038/s41419-019-1968-4>.
82. Pan, A., Sun, X.-M., Huang, F.-Q., Liu, J.-F., Cai, Y.-Y., Wu, X., Alolga, R.N., Li, P., Liu, B.-L., Liu, Q., et al. (2022). The mitochondrial  $\beta$ -oxidation enzyme HADHA restrains hepatic glucagon response by promoting  $\beta$ -hydroxybutyrate production. *Nat. Commun.* 13, 386. <https://doi.org/10.1038/s41467-022-28044-x>.
83. Yang, J.H., Kim, N.H., Yun, J.S., Cho, E.S., Cha, Y.H., Cho, S.B., Lee, S.-H., Cha, S.-Y., Kim, S.-Y., Choi, J., et al. (2020). Snail augments fatty acid oxidation by suppression of mitochondrial ACC2 during cancer progression. *Life Sci. Alliance* 3, 3. <https://doi.org/10.26508/lsa.202000683>.
84. Peng, H., Wang, Y., and Luo, W. (2020). Multifaceted role of branched-chain amino acid metabolism in cancer. *Oncogene* 39, 6747–6756. <https://doi.org/10.1038/s41388-020-01480-z>.
85. White, P.J., McGarrah, R.W., Grimsrud, P.A., Tso, S.-C., Yang, W.-H., Haldeman, J.M., Grenier-Larouche, T., An, J., Lapworth, A.L., Astapova, I., et al. (2018). The BCKDH kinase and phosphatase integrate BCAA and